

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|--|
| ☐ | ☒ | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☐ | ☒ | A description of all covariates tested |
| ☐ | ☒ | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☐ | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☒ | ☐ | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	All raw sequencing data have been submitted to the NCBI Sequence Read Archive (SRA, https://www.ncbi.nlm.nih.gov/sra) under the project number of PRJNA864839. All other data are available in the main text or supplementary materials.
Data analysis	The analysis code and data matrices (genetic distances, geographic distances and temporal distances) are available at: https://github.com/emilyli0325/Malaria-genomics-in-Eastern-Myanmar .

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All raw sequencing data have been submitted to the NCBI Sequence Read Archive (SRA, <https://www.ncbi.nlm.nih.gov/sra>) under the project number of

PRJNA864839. The data matrices (genetic distances, geographic distances and temporal distances) are available at: <https://github.com/emilyli0325/Malaria-genomics-in-Eastern-Myanmar>.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	NA. This study analysed <i>Plasmodium falciparum</i> parasite genomes derived from anonymized clinical samples, and no human participant data (including sex or gender) were collected or analysed.
Reporting on race, ethnicity, or other socially relevant groupings	NA. No human demographic information, including race, ethnicity, or socially defined groupings, was collected or analysed. Analyses were performed on parasite genomic data only.
Population characteristics	NA. Human participant characteristics were not analysed. The study focused on parasite population genomics using anonymized dried blood spot samples collected through malaria surveillance programmes.
Recruitment	NA. Human participants were not recruited for research purposes. Samples were collected as part of routine malaria surveillance and elimination programmes, and were analysed in anonymized form for parasite genomic studies.
Ethics oversight	The METF program was approved by the Department of Medical Research (Lower Myanmar) 73/Ethics 2014 and OxTREC (reference no. 1017-13).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We used malaria dried blood spot (DBS) samples available from longitudinal sampling of <i>Plasmodium falciparum</i> in Eastern Myanmar (n=5014). Power calculations were not conducted, but the numbers far exceed those needed to identify temporal or spatial trends.
Data exclusions	No data were excluded from these analyses.
Replication	This was an observational cohort study, and replication was not conducted. However, we demonstrated that the observed impact of mass drug administration (MDA) is reproducible across similar settings.
Randomization	No randomization was conducted for these analyses.
Blinding	Blinding was not relevant to these experiments

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Plants

Seed stocks	NA
Novel plant genotypes	NA
Authentication	NA